甲状腺术后声带麻痹口服糖皮质激素治疗:一项随机临床试验
这项前瞻性随机双盲安慰剂对照试验于2018年9月至2023年5月在三级转诊医院纳入468例接受甲状腺或甲状旁腺手术的患者,其中26例(5.6%)出现单侧声带麻痹并随机接受7天口服糖皮质激素或安慰剂。第7天激素组声带恢复率为42.8%(6/14),安慰剂组为41.6%(5/12),比例差1.2%(95%CI -32.8%至34.4%),GRBAS各时间点组间无有意义的差异。作者认为口服糖皮质激素未增强声带恢复或改善嗓音质量,言语治疗仍是术后声带麻痹管理的关键。
要点
- 26例术后单侧声带麻痹患者随机接受7天口服糖皮质激素或安慰剂。
- 第7天声带恢复率激素组42.8%(6/14)vs 安慰剂组41.6%(5/12),比例差1.2%(95%CI -32.8%至34.4%)。
- GRBAS各时间点组间病理项目无有意义的差异。
核心结论
- 作者认为口服糖皮质激素未增强术后单侧声带麻痹患者的声带恢复或改善嗓音质量。
- 作者指出言语治疗仍是术后声带麻痹管理的关键。
研究设计与样本
- 前瞻性随机双盲安慰剂对照试验,于2018年9月至2023年5月在三级转诊医院开展。
- 纳入接受部分或全甲状腺切除术或甲状旁腺手术的患者,排除糖皮质激素不耐受、既往颈部手术或放疗、恶性肿瘤手术及多结节性胸骨后甲状腺肿者。
- 共纳入468例患者,26例(5.6%)出现单侧声带麻痹并随机分组;激素组中位年龄68岁(IQR 62.5-73.0),安慰剂组59岁(IQR 52.5-73.0);男性19.2%,女性80.8%。
- 所有分析均为意向性治疗分析。
主要发现
- 第7天声带恢复率激素组为42.8%(6/14),安慰剂组为41.6%(5/12),比例差1.2%(95%CI -32.8%至34.4%)。
- GRBAS结果在各时间点组间病理项目均无有意义的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is no consensus in the field for the management of postthyroidectomy unilateral vocal fold paralysis (VFP). In cases where recurrent laryngeal nerve transection is not present, a local inflammatory process is thought to cause VFP. The findings suggest that corticosteroids may have a beneficial effect in managing this phenomenon. OBJECTIVE: To evaluate the efficacy of a 7-day oral corticosteroid treatment on vocal cord remobilization in patients with unilateral VFP after thyroidectomy or parathyroid surgery. DESIGN, SETTING, AND PARTICIPANTS: This prospective randomized double-blind placebo-controlled trial was conducted between September 2018 and May 2023 at a tertiary referral hospital. Patients who underwent partial or total thyroidectomy or parathyroid surgery were included. Exclusion criteria included corticosteroid intolerance, prior cervical surgery or radiotherapy, surgery performed for a malignant tumor and multinodular intrathoracic goiters. INTERVENTIONS: At baseline, an inclusion visit assessed vocal cord mobility via nasofibroscopy and voice quality using the GRBAS (grade, roughness, breathiness, asthenia, strain) scale. Postoperative assessments were performed the day after surgery to identify unilateral VFP. Patients with unilateral VFP were randomized to receive either a 7-day course of oral corticosteroids or a placebo. MAIN OUTCOMES AND MEASURES: At 7 days, 1 month, and 3 months, nasofibroscopic evaluation and GRBAS scale assessment were performed to monitor vocal fold remobilization and voice quality. All analyses were intention to treat. RESULTS: Of the 468 patients included, 26 (5.6%) developed unilateral VFP and were randomized (19.2% male; 80.8% female; median age, 68 [IQR, 62.5-73.0] years in corticosteroid group and 59 [IQR, 52.5-73.0] years in placebo group). By day 7, vocal cord remobilization occurred in 42.8% (6 of 14) of the corticosteroid group and 41.6% (5 of 12) of the placebo group (proportion difference, 1.2%; 95% CI -32.8% to 34.4%). GRBAS results showed no meaningful difference in pathological items between groups at any time point. CONCLUSION AND RELEVANCE: Results of this randomized clinical trial suggest that oral corticosteroids do not enhance vocal cord remobilization or improve voice quality in patients with postoperative unilateral VFP. Speech therapy remains essential in the management of postoperative VFP. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03553342.
引用
- Carvajal-Alegria E, Girault N, Donatini G, et al. Oral Corticosteroids in Vocal Fold Paralysis After Thyroid Surgery: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40773211. doi:10.1001/jamaoto.2025.2169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。